Precision BioSciences, Inc. (NASDAQ:DTIL) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $32.25.

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday, August 5th. Oppenheimer initiated coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Wall Street Zen downgraded shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th.

Precision BioSciences Stock Performance

DTIL opened at $7.78 on Friday. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $9.62. The business has a 50 day moving average of $7.82 and a 200-day moving average of $6.76. The stock has a market cap of $214.73 million, a price-to-earnings ratio of -2.78 and a beta of 1.27.

Precision BioSciences (NASDAQ:DTIL) last posted its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. On average, equities research analysts expect that Precision BioSciences will post -3.33 earnings per share for the current year.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after purchasing an additional 4,025 shares during the period. Miller Financial Services LLC boosted its stake in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after purchasing an additional 5,000 shares during the period. Lynx1 Capital Management LP boosted its stake in Precision BioSciences by 0.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after purchasing an additional 6,545 shares during the period. Quarry LP grew its holdings in Precision BioSciences by 15.1% in the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock valued at $284,000 after buying an additional 8,936 shares in the last quarter. Finally, HBK Sorce Advisory LLC acquired a new position in Precision BioSciences in the 4th quarter valued at $38,000. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.